**Case report of acute type 2 respiratory failure secondary to Colistin**
Mushtak Talib Abbas Algherbawe¹, Awad Wanas Awad¹

¹ Medical Department, Sur Hospital, Sur, Oman.
Correspondence to Mushtak Talib Abbas Algherbawe (E mail: m_algherbawe@yahoo.com)
(Submitted: 19 March 2019 – Revised version received: 28 March 2019 – Accepted: 27 April 2019 – Published online: 26 September 2019)

**Abstract** We report an elderly patient who developed type 2 respiratory failure after receiving Colistimethate (CMT). The patient has chronic kidney disease, and was admitted to Medical Intensive Care Unit with Pneumococcal pneumonia. However, he had nosocomial *Acinetobacter baumannii* urinary tract infection, which was only sensitive to colistin. Unfortunately, 72 h after initiation of Colistimethate, his consciousness deteriorated. 5 days later, he passed into acute type 2 respiratory failure. All investigations were done and no cause was found so, Colistin-induced respiratory failure was presumed hence, the drug was withdrawn, and his condition improved within 48 h and was extubated 4 days later.

**Keywords** Colistin, neurotoxicity, respiratory failure.

**Introduction**
Polymyxins were discovered in 1947 from different species of *Bacillus polymyxa*.¹ ² This class of antibiotics consists of five chemically different compounds, polymyxin A, B, C, D, and E (colistin). Only polymyxins B (PMB) and E have been used in clinical practice.³ Both of them exert a bactericidal effect on the cell wall of Gram-negative bacteria, causing permeability changes in the cytoplasmic membrane leading to cell death.⁴ Their use was abandoned in 1970s and replaced with other antibiotics because of concerns related to toxicity (kidney and neurotoxicity).⁵ ⁶ However, there was a renewed interest into colistin use due to multidrug-resistant(MDR) Gram-negative bacteria, in particular *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Klebsiella pneumoniae*.⁷ ⁸ Our patient had *Acinetobacter baumannii* which was MDR, so this is the reason colistin was chosen.

**Case Report**
A 73-year-old male presented with fever, cough of yellowish sputum of 4-day duration. He is a known case of type 2 diabetes, hypertension, chronic kidney disease, ischemic heart disease and old cerebrovascular accident with left-sided hemiplegia.

On examination: he was cyanosed with a pulse rate of 121/min, blood pressure of 90/45 mm Hg, temperature of 38.5°C. His investigations shown in table revealed evidence of septic, metabolic changes were found (Table 1). Chest radiograph was normal (picture-2), electrocardiogram showed tachycardia. His echocardiogram showed normal right ventricular diameters and normal pulmonary artery pressure and his non contrast CT of his head showed old changes with no bleeds, new infarction or edema. It was suspected that colistimethate was the culprit therefore, it was discontinued. Having reviewed tigecycline trials in urinary tract infections in literatures, it was started instead. Within 48 h, his consciousness improved then, he started to communicate, and retain muscle power thence, he was extubated. A week later, he was discharged from the Medical Intensive Care in a stable condition.

**Discussion**
The interaction of colistin with colinurs, which have high lipid content, has been associated with the occurrence of neurotoxicity.⁹

Similarly, neuromuscular blockade presenting as a myasthenia-like syndrome or as respiratory muscle paralysis producing apnea has been reported.¹⁰ The possible mechanism is a non-competitive myoneuronal presynaptic blockade of acetyl-cholinesterase that may be enhanced by hypocalcaemia-induced prolongation depolarization.¹¹ Calcium infusion has been proposed to reverse paralysis but no benefit from neostigmin.¹² Lindesmith et al described 21 cases of reversible...
Case report
Case report of acute type 2 respiratory failure
Mushtak Talib Abbas Algherbawe and Awad Wanis Awad


respiratory paralysis in 1968; 15 cases were associated with CMS and 6 cases with PMB therapy.13,14,15,16,17,18,19 Concomitant drug therapies including other anesthetics, muscle relaxant, corticosteroids, and narcotics probably increase the risk of CMS neurotoxicity.6 Our patient has no new neurological insult such as stroke and he did not received muscle relaxants or steroids but Fentanyl. His calcium, potassium, and magnesium were normal, there were no tetany, arrhythmia, seizure, or involuntary movements.

The majority of respiratory failure related to polymyxin-associated neuromuscular blockade was described in patients with chronic kidney disease.19 Likewise, our patient has chronic kidney disease and received intravenous colistin which may have lead to apnea 5 days after commencing the medicine. This can readily be supported by his normal parameters including serum electrolytes, white cell differential, chest X-ray, echocardiography and brain CT. A more confirmatory finding: his consciousness, breathing as well as arterial blood gases and renal functions returned back to their base line once the medication was stopped.

Conclusion
Due to presence of MDR bacteria and re-usage of colistin, the awareness of colistin-induced respiratory failure must be kept in mind as this is serious side effect. Patients receiving these drugs should have regular reviews for drug–drug interactions, as well as renal and neurological assessments.8 Vigilance of the shortness of breath can facilitate the diagnosis of colistin-mediated respiratory failure in a patient with shortness of breath of unknown cause.

Acknowledgements
Declared none.

References
4. Zhiliang Yu, Yuanning Cai, Wangrong Qin, Polymyxin E Induces rapid Paenibacillus polymyxa death by damaging cell membrane while Ca2+ can protect cells from damage. PLoS One. 2015; 10(8)

Table 1.

<table>
<thead>
<tr>
<th>Labs</th>
<th>On admission</th>
<th>One week after admission</th>
<th>After colistin &amp; before second intubation</th>
<th>Before Discharge from ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>White blood cell</td>
<td>21 x10^3/μL</td>
<td>9.8 x10^3/μL</td>
<td>12.2 x10^3/μL</td>
<td>6.5 x10^3/μL</td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>224.45 mg/L</td>
<td>98 mg/L</td>
<td>117 mg/L</td>
<td>36 mg/L</td>
</tr>
<tr>
<td>Creatinine</td>
<td>289 umol/L</td>
<td>172 umol/L</td>
<td>200 umol/L</td>
<td>167 umol/L</td>
</tr>
<tr>
<td>Potassium</td>
<td>4.4 mmol/L</td>
<td>3.8 mmol/L</td>
<td>4.3 mmol/L</td>
<td>4.1 mmol/L</td>
</tr>
<tr>
<td>Magnesium</td>
<td>0.86 mmol/L</td>
<td>0.69 mmol/L</td>
<td>0.72 mmol/L</td>
<td>0.76 mmol/L</td>
</tr>
<tr>
<td>Corrected calcium</td>
<td>2.46 mmol/L</td>
<td>2.2 mmol/L</td>
<td>2.3 mmol/L</td>
<td>2.4 mmol/L</td>
</tr>
</tbody>
</table>

Fig. 1